We focused on those signaling components that were significantly different between control and insulin-like molecule treatment (that is, IR, IGF1R, p-Erk and p-Akt) and evaluated all EMT tumors (n = 123; the major tumor type irrespective of treatment condition), thereby eliminating tumor type variation. This evidence concerns the gene INS and neoplasm.